Clinical Study
Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China
Table 4
Adverse events frequency and severity.
| | | SOF+DCV
N=96 | SOF+LDV
N=99 | SOF+VEL
N=31 | Total
N=226 |
| | Fatigue | 18(19%) | 34(34%) | 6(19%) | 58(26%) | | Diarrhea | 8(8%) | 13(13%) | 2(6%) | 23(10%) | | Headache | 16(17%) | 14(14%) | 2(6%) | 33(15%) | | Nausea | 10(10%) | 6(7%) | 3(10%) | 19(8%) | | Vomiting | 4(4%) | 7(7%) | 2(6%) | 13 (6%) | | Insomnia | 7(7%) | 14(14%) | 4(13%) | 25(11%) | | Dizziness | 6(6%) | 21(21%) | 3(10%) | 30(13%) | | Cough | 6(6%) | 12(12%) | 5(16%) | 23(10%) | | Adverse event leading to discontinuation | 0 | 0 | 0 | 0 | | HCC occurrence during therapy | 0 | 0 | 0 | 0 | | HCC occurrence during 12 weeks of follow-up period | 0 | 0 | 0 | 0 |
|
|
